Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)

Terminated

Phase 2 Results

Summary of Purpose

The purpose of this study is to determine which of 3 different doses of tenecteplase (TNK) is better for treating stroke patients and if TNK offers an advantage over currently available treatment with tissue plasminogen activator (tPA). Trial Stopped: Slow enrollment

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 26 February 2015.

1 Nov 2005 10 Nov 2005 1 Mar 2009 1 Sep 2009 1 Feb 2015 12 Jan 2015
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator)
  • Purpose: Treatment
  • Intervention: Parallel Assignment

Contacts

  • 1st contact: Martha Davis, R.N. Phone: 434-243-6319 2nd Contact: Anita Tierney, MPH Phone: 212-342-1259

    cab7u@virginia.edu